Expanded Colorectal Cancer Claim Moves Avastin Toward Continuous Use
This article was originally published in The Pink Sheet Daily
FDA approves use of Genentech’s bevacizumab for second-line treatment of metastatic colorectal cancer patients who have progressed on a first-line, Avastin-containing chemotherapeutic regimen.
You may also be interested in...
A better value proposition and more in-tune marketing ideas would drive a more creative risk-sharing or asset swap-like arrangement for the oncology specialist’s more mature brands, says Roche CEO Severin Schwan.
Genentech’s bevacizumab was associated with improved maintenance of baseline quality of life and performance status in a confirmatory trial conducted under accelerated approval, but an NCI-funded study found higher rates of neurocognitive decline, increased symptom severity and decline in health-related quality of life.
Genentech’s HER2 program director Dietmar Berger shares broader plans for Kadcyla (ado-trastuzumab emtansine) following its approval in second-line mBC, and expects Herceptin will continue to play a role in the long term.